Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: BOD to acquire Aqua Phase on positive data; Bionomics set to delist
News
Top 10 at 10: Who’s planning to tap a $6bn Chinese market?
News
Market Highlights: Wall Street rises ahead of Big Tech earnings; Goldman says more upside for stocks in 2023
Health & Biotech
ASX Health Stocks: Successful toxicology tests pave the way for PYC’s Phase 2 clinical trial
News
In Case You Missed It: Lithium, rare earth and pharma players do the heavy lifting
News
Market Highlights: New banking crisis as First Republic seeks a lifeline; and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Osteopore licenses its bone regeneration technology; Kazia resolves problem with Nasdaq
News
In Case You Missed It: Rare earths, rare earths, a biotech and more rare earths
News
Market Highlights: Aussie becomes first to sue ChatGPT for defamation, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Patrys crashes after Phase 1 delayed till 2024, Nova Eye surges 20pc on FDA OK
Health & Biotech
Osteopore acquires multiple medical distribution businesses, closing in on cash flow positive
News
Market Highlights: ASX to surge on Big Tech rally; and 5 small caps to watch on Monday
News
Closing Bell: ASX finishes down 0.21% as the market limps towards Xmas
News
LAST ORDERS: A sleepy look back Monday’s news you might have missed
Health & Biotech
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results
Health & Biotech
On the nose – Osteopore taps into lucrative rhinoplasty market with bioresorbable polymer scaffold
News